玻璃体视网膜淋巴瘤的诊断进展
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Recent progress in the diagnosis of vitreoretinal lymphoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    玻璃体视网膜淋巴瘤(VRL)是罕见的恶性非霍奇金淋巴瘤,因无特异性临床表现,对其早期、正确地诊断仍面临很大的挑战。病理细胞学诊断是VRL诊断的金标准,但其诊断仍需要结合临床表现、影像学检查、免疫学及分子学检测等。随着诊断技术的进步,更加高效的细胞学检查及辅助诊断技术不断被探索。细胞因子及眼内淋巴瘤诊断的白介素评分(ISOLD)、髓样分化因子88(MYD88)基因突变及二代测序检测技术有良好的诊断效能而逐渐成为重要的辅助诊断手段及研究热点。

    Abstract:

    Vitreoretinal lymphoma(VRL)is a rare and aggressive non-Hodgkin's lymphoma, and its early and correct diagnosis is still a great challenge because of its non-specific clinical presentation. For VRL diagnosis, pathological cytology is still the gold standard, but its diagnosis needs to combine with clinical manifestations, imaging features, immunological and molecular technology and so on. With the advancement of diagnostic technology, more efficient techniques of cytology and assistant diagnosis have been explored. Cytokines and interleukin score for intraocular lymphoma diagnosis(ISOLD), myeloid differentiation gene 88(MYD88)mutation and next-generation sequencing have higher diagnostic accuracy, so they have gradually become important auxiliary diagnostic methods and research hotspots.

    参考文献
    相似文献
    引证文献
引用本文

田莎,陈锟,王庆平.玻璃体视网膜淋巴瘤的诊断进展.国际眼科杂志, 2022,22(9):1468-1472.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2021-12-08
  • 最后修改日期:2022-07-29
  • 录用日期:
  • 在线发布日期: 2022-09-02
  • 出版日期:
文章二维码